Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tritanrix-HepB
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tritanrix-HepB is a combination vaccine developed by GSK Biologicals. It is a DTPw-HBV vaccine, meaning it provides protection against Diphtheria, Tetanus, whole-cell Pertussis, and Hepatitis B. The vaccine is administered as a primary vaccination course to healthy infants. A version with low thiomersal content, referred to as Tritanrix™-HepB low thio, has also been developed.
- Brand names
- Tritanrix-HepB
- Other names
- Tritanrix™-HepBTritanrix™-HepB low thio
02
Targets
HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Tritanrix-HepB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tritanrix-HepB.